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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized
by the development of multiple hamartomas in many internal organs. Mutations in either one of 2
genes, TSC1 and TSC2, have been attributed to the development of TSC. More than two-thirds of
TSC patients are sporadic cases, and a wide variety of mutations in the coding region of the TSC1
and TSC2 genes have been reported.
Methods: Mutational analysis of TSC1 and TSC2 genes was performed in 84 Taiwanese TSC
families using denaturing high-performance liquid chromatography (DHPLC) and direct sequencing.
Results: Mutations were identified in a total of 64 (76 %) cases, including 9 TSC1 mutations (7
sporadic and 2 familial cases) and 55 TSC2 mutations (47 sporadic and 8 familial cases). Thirty-one
of the 64 mutations found have not been described previously. The phenotype association is
consistent with findings from other large studies, showing that disease resulting from mutations to
TSC1 is less severe than disease due to TSC2 mutation.
Conclusion: This study provides a representative picture of the distribution of mutations of the
TSC1 and TSC2 genes in clinically ascertained TSC cases in the Taiwanese population. Although
nearly half of the mutations identified were novel, the kinds and distribution of mutation were not
different in this population compared to that seen in larger European and American studies.
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Background
Tuberous sclerosis complex (TSC) is an autosomal domi-
nant disorder having an incidence of 1 in 6,000 to 1 in
10,000 live births [1]. The severity of TSC and its impact
on the quality of life are extremely variable among
patients [2]. Common clinical manifestations of this dis-
ease include intellectual handicap, autistic disorders, and
epilepsy due to the frequent, widespread occurrence of
cortical tubers, which are focal disruptions of the cortical
architecture due to undifferentiated giant cells. Hamarto-
mas are also found in multiple other organ systems,
including the heart, lungs, kidneys, and skin [3].
Patients often seek medical attention for dermal lesions or
frequent seizures. The clinical diagnostic guidelines on
TSC were prepared based on clinical features, radio-
graphic findings, and histopathological findings [3].
Accurate clinical diagnoses are relatively easy in patients
with classic multisystem involvement, but are often diffi-
cult due to the diversity of clinical findings in TSC
patients.
The genetic basis of TSC has been determined to be due to
mutation in either one of two unlinked genes, TSC1 and
TSC2 [4]. The human TSC1 gene on chromosome 9q34
consists of 23 exons giving an 8.6-kb mRNA transcript,
which has a coding region of 3.5-kb and encodes a 130-
kDa protein spanning 1164 amino acids [5]. The TSC2
gene, which is located on chromosome 16p13.3, contains
41 exons and encodes a 200-kDa protein with 1807
amino acid [4,6]. Both TSC1 and TSC2 are tumor suppres-
sor genes and their protein products, hamartin and
tuberin, respectively, form a complex that regulates the
mammalian target of rapamycin (mTOR) in the phosph-
oinositide 3-kinases (PI3-kinase)/AKT pathway to control
cellular proliferation, adhesion, growth, differentiation or
migration [7,8]. Furthermore, both genes play a role in
cortical differentiation and growth control.
The mutation spectra of the TSC genes are very heteroge-
neous and no hotspots for mutations have been reported.
There are many mutations in each gene that are seen
recurrently, but no single mutation accounts for more
than about 1% of all TSC patients. TSC2 mutations are
about five times more common than TSC1 mutations [9]
and new mutations are typically found in the two-thirds
of TSC cases that are sporadic [10]. Despite complete pen-
etrance of the disease in TSC patients, phenotypic variabil-
ity can make the determination of disease status difficult
among family members of affected individuals.
In this study, we analyzed both TSC1 and TSC2 genes in
84 independent Taiwanese TSC probands for whom
detailed information on clinical manifestations and phe-
notype were available. Furthermore, we also assessed the
mutational distribution and possible genotype-pheno-
type correlations between and within the two genes.
Methods
Patient Population
This study was approved by the Ethics Committee of the
Division of Obstetrics and Gynecology, National Taiwan
University Hospital. Eighty-four unrelated patients with
confirmed clinical diagnoses of TSC and their family
members were tested for mutations in TSC1 and TSC2
genes.
The general clinical features of TSC patients were deter-
mined by clinicians in accordance with the TSC diagnosis
criteria set forth by the Tuberous Sclerosis Consensus
Conference [3]. All patients' symptoms were investigated
by a person blind to mutational status. High-resolution
brain magnetic-resonance imaging (MRI) or computed
tomography (CT) was performed on most patients.
The extent of facial angiofibroma or forehead plaques,
non-traumatic ungal or periungal fibromas, hypomelan-
otic macules, shagreen patches, multiple retinal nodular
hamartomas, cortical tubers, subependymal nodules, sub-
ependymal giant cell astrocytomas, cardiac rhabdomyo-
mas, lymphangiomyomatoses, renal angiomyolipomas
and confetti-like lesions were all assessed. Moreover, most
patients' medical histories of mental development were
assessed by a certified psychologist.
Sample Preparation
After genetic counseling and obtaining informed consent,
5–10 mL of peripheral blood were collected from the par-
ticipants. Genomic DNA was isolated from peripheral
whole blood using the Puregene DNA Isolation Kit (Gen-
tra Systems, Inc., Minneapolis, MN, USA).
Mutational Analysis of TSC Genes
PCR primers and running conditions for each exon were
available from previous studies [11-13]. The PCR reaction
was run on each exon with a total sample volume of 25 µL
containing 100 ng of genomic DNA, 0.12 µM of each
respective primer, 100 µM dNTPs, 10 mM Tris-HCl (pH
8.3), 50 mM KCl, 2 mM MgCl2, and 0.5 units of AmpliTaq
Gold enzyme (PE Applied Biosystems, Foster City, CA,
USA). Amplification was performed in a multiblock sys-
tem thermocycler (ThermoHybaid, Ashford, UK). The
PCR amplification started with a denaturing step at 95°C
for 5 minutes, followed by 35 cycles of denaturing at
94°C for 30 seconds, annealing at melting temperature
(Tm) for 30 seconds, extension at 72°C for 45 seconds,
and ends with a final extension step at 72°C for 10 min-
utes.BMC Medical Genetics 2006, 7:72 http://www.biomedcentral.com/1471-2350/7/72
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The screening of mutations was performed using the
Transgenomic Wave Nucleic Acid Fragment Analysis Sys-
tem (Transgenomic Inc, San Jose, CA) with a C18 reversed-
phase column containing 2-µm nonporous poly (styrene/
divinylbenzene) particles (DNASep Column, Transge-
nomic Inc). PCR products were analyzed using linear ace-
tonitrile gradients and triethylammonium acetate acting
as mobile phases with the provision of buffer A (0.1 M
TEAA) and buffer B (0.1 M TEAA with 25% acetonitrile)
(WAVE Optimized, Transgenomic Inc). Heteroduplex
analyses were performed according to the manufacturer's
protocol and of previous studies [14,15].
Statistical method
The χ2 and Fisher exact tests were used to examine the dif-
ferences in clinical manifestations, phenotypes, and
mutation distributions in independent Taiwanese
probands between patients with TSC1 and TSC2 genes.
Direct Sequence Analysis
PCR products were purified by solid-phase extraction and
bidirectionally sequenced using Applied Biosystems' Taq
DyeDeoxy terminator cycle sequencing kit (Applied Bio-
systems). Sequencing reactions were separated on a PE
Biosystems 373A/3100 sequencer.
Results and Discussion
Identification and Characterization of Mutations
In the current study, we performed mutational analysis on
the coding exons and the exon/intron junctions of both
TSC1 and TSC2 in a total of 84 individuals with TSC and
their family members. The determination of mutation vs.
polymorphism was done by: 1) checking the mutation
tables at the Chromium site (http://chromium.liacs.nl/);
2) comparison of findings to those of 100 healthy Taiwan-
ese controls; and 3) checking the families similarly.
Nine mutations were identified in the TSC1 gene while 55
were identified in the TSC2 gene. Mutations in the TSC1
gene included five nonsense mutations with early termi-
nation codons and four insertions/deletions which
caused frameshifts and resulted in premature truncation
of the protein. Three of these mutations were novel, while
six were previously reported (Table 1).
The 55 mutations in the TSC2 gene included 12 missense,
15 nonsense, 21 frameshifts due to insertions and dele-
tions and 7 putative splice-site mutations. Twenty-seven
of these mutations were previously reported while 28
were novel (Table 2). Of the familial TSC2 missense muta-
tions, A1141T and R1793Q may be rare polymorphic var-
iants co-segregating with TSC. There was no direct
evidence that these familial TSC2 missense mutational
changes were pathogenic.
For both genes, sequence variants that were possible
mutations were tested in all other family members,
including the parents and both the affected and the unaf-
fected family members. In total, 31 of the 64 mutations
(48%) had not been reported elsewhere. Moreover, no
mutational hotspots were identified in either gene, with
only four different mutations being found twice in TSC2.
Compared with those of European and American counter-
parts [9,10,16], the distribution of the TSC1 and TSC2
mutations among Taiwanese population is similar. There-
fore, the spectrum of mutations seen among the Taiwan-
ese is no different in comparison to those already reported
thus far for these two genes, based on the genetic analyses
of European and American TSC patients using the Fisher
exact test (P  = 0.85, 0.46, and 0.14, respectively).
Table 1: Status of TSC1 mutations in Taiwanese patients with TSC
No. Gene Exon Nucleotide change Codon change Mutation type Inheritance Reported Reference
62 TSC1 7 c.602_604del CCT In-frame deletion S N This study
61 TSC1 15 c.1525C>T p.R509X Nonsense F R [5]
72 TSC1 15 c.1791_1792dupAA Frameshift S N This study
2 TSC1 15 c.1884_1887delAAAG Frameshift F R [5]
36 TSC1 15 c.1959dupA Frameshift S R LOVD*
54 TSC1 17 c.2074C>T p.R692X Nonsense S R [5]
31 TSC1 18 c.2283C>A p.Y761X Nonsense S R [24]
3 TSC1 18 c.2332C>T p.Q778X Nonsense S N This study
41 TSC1 18 c.2356C>T p.R786X Nonsense S R [5]
Total: 9, F:2, S:7, N:3, R:6 MM:0, NM:5, FM:4, SM:0.
F: familial case, S:sporadic case.
N: non-reported, R: reported.
MM: missense mutations, NM: nonsense mutations, FM: frameshift/in-frame mutations, SM: splicing site mutations.
* The the Leiden Open (source) Variation Database which was available at http://chromium.liacs.nl/lovd/.BMC Medical Genetics 2006, 7:72 http://www.biomedcentral.com/1471-2350/7/72
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Table 2: Status of TSC2 mutations in Taiwanese patients with TSC
No. Gene Exon Nucleotide change Codon change Mutation type Inheritance Reported Reference
21 TSC2 1 c.109dupG Frameshift F N This study
30 TSC2 1 c.133_136delCTGA Frameshift S R DK*
35 TSC2 3 c.268C>T p.Q90X Nonsense S R [25]
47 TSC2 6 c.632delC Frameshift S N This study
8 TSC2 intron 8 c.848+3delG Splicing S N This study
37 TSC2 9 c.856A>G p.M286V Missense F R [10]
78 TSC2 10 c.1060C>T p.Q354X Nonsense S N This study
75 TSC2 10 c.1117C>T p.Q373X Nonsense S R DK*
48 TSC2 11 c.1226_1230delAACTG Frameshift S N This study
12 TSC2 12 c.1336C>T p.Q446X Nonsense S R [25]
20 TSC2 14 c.1513C>T p.R505X Nonsense S R [10]
57 TSC2 14 c.1513C>T p.R505X Nonsense S R [10]
65 TSC2 intron 14 c.1599+2T>C Splicing S N This study
76 TSC2 16 c.1794C>G p.Y598X Nonsense S R [10]
29 TSC2 16 c.1832G>A R611Q Missense S R [10]
59 TSC2 intron 16 c.1840-2A>T Spilicing S N This study
82 TSC2 17 c.1939G>A p.D647N Missense S R [26]
7 TSC2 18 c.2086T>C p.C696R Missense S R [27]
53 TSC2 19 c.2103_2105dupTGA In-frame insertion S N This study
5 TSC2 19 c.2210T>C p.L737P Missense S N This study
23 TSC2 20 c.2251C>T p.R751X Nonsense S R [10]
70 TSC2 20 c.2251C>T p.R751X Nonsense S R [10]
39 TSC2 21 c.2404dupA Frameshift F N This study
32 TSC2 21 c.2461A>T p.K821X Nonsense S N This study
11 TSC2 21 c.2538delC Frameshift F N This study
67 TSC2 intron 21 c.2546-2A>T Splicing S N This study
73 TSC2 intron 22 c.2639+1G>C Splicing S R [9]
22 TSC2 23 c.2641delT Frameshift F N This study
27 TSC2 24 c.2824G>T p.Q942X Nonsense S N This study
64 TSC2 26 c.2974C>T p.Q992X Nonsense S R [28]
80 TSC2 26 c.3076dupT Frameshift S N This study
33 TSC2 28 c.3389delC Frameshift S N This study
19 TSC2 29 c.3412C>T p.R1138X Nonsense S R [9]
42 TSC2 29 c.3421G>A p.A1141T Missense F N This study
13 TSC2 30 c.3693_3696delGTCT Frameshift S R DK*
51 TSC2 30 c.3696dupT Frameshift S N This study
9 TSC2 33 c.4175_4176delAG Frameshift S N This study
26 TSC2 33 c.4440dupA Frameshift S N This study
77 TSC2 34 c.4541_4544delCAAA Frameshift S R [12]
18 TSC2 35 c.4603_4605delGAC In-frame deletion S N This study
34 TSC2 35 c.4603G>T p.D1535Y Missense S N This study
83 TSC2 36 c.4830G>A p.W1610X Nonsense S R DK*
28 TSC2 36 c.4846C>T p.Q1616X Nonsense S N This study
16 TSC2 37 c.4909_4910delAA Frameshift S N This study
81 TSC2 38 c.5032dupT Frameshift S N This study
60 TSC2 39 c.5150T>C p.L1717P Missense S R [29]
55 TSC2 intron 39 c.5160+3G>C Splicing S N This study
43 TSC2 intron 39 c.5160+4A>G Splicing S R [29]
4 TSC2 40 c.5227C>T p.R1743W Missense S R DK *
50 TSC2 40 c.5227C>T p.R1743W Missense S R DK*
56 TSC2 40 c.5228G>A p.R1743Q Missense F R [30]
10 TSC2 40 c.5238_5255del18 Frameshift S R [31]
25 TSC2 40 c.5238_5255del18 Frameshift S R [31]
6 TSC2 40 c.5252_5259+19del27 Frameshift S R [9]
15 TSC2 41 c.5378G>A p.R1793Q Missense F N This study
Total: 55, F:8, S:47, N:28, R:27 MM:12, NM:15, FM:21, SM:7.
F: familial case, S:sporadic case.
N: non-reported, R: reported.
MM: missense mutations, NM: nonsense mutations, FM: frameshift/in-frame mutations, SM: splicing site mutations.
* The database of Dr David Kwiatkowski which was available at http://tsc-project.partners.org/.BMC Medical Genetics 2006, 7:72 http://www.biomedcentral.com/1471-2350/7/72
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Identification and Characterization of Polymorphism
In order to identify whether the observed changes were
mutations or polymorphisms, samples from 100 normal
individuals serving as controls were analyzed. Changes
that were not found in more than 200 control alleles were
considered pathogenic. Therefore, unique or less frequent
changes such as missense and splicing site mutations
(Table 2) were considered likely pathogenic mutations.
The nonpathogenic TSC1 and TSC2 mutations identified
in the Taiwanese TSC patients are described in Table 3. We
identified nine nonpathogenic polymorphisms in the
TSC1 gene and 12 in the TSC2 gene. The nonpathogenic
sequence variants were identified in both the TSC patients
and the normal controls. Fourteen of these polymor-
phisms had not been reported previously (4 at the TSC1
locus and 10 at the TSC2 locus) that included one mis-
sense variant within the TSC1 coding region.
Genotype-Phenotype Correlation: Familial or Sporadic 
TSC mutations
Mutations were identified and located in exons of both
TSC1 and TSC2 genes (see Figure 1 and 2). Of the 64
mutations found, nine and 55 were associated with TSC1
(14%) and TSC2 (86%), respectively, as shown in Table 4.
Of the 10 familial cases, 2 (20%) and 8 (80%) were
TSC1and  TSC2  mutations, respectively. Among the 54
sporadic cases, 7 TSC1 (13%) and 47 TSC2 (87%) muta-
tions were found. Accordingly, there was no significant
difference between sporadic and familial TSC cases with
respect to the frequency of TSC1 vs TSC2 mutation (P =
0.62).
Genotype-Phenotype Correlation: Clinical Manifestations
The clinical characteristics associated with each mutation
in the proband are shown in Tables 5 (eight TSC1 muta-
tions) and Table 6 (43 TSC2 mutations). Most patients
with  TSC1  and  TSC2  mutations had seizures, brain
lesions (subependymal nodules and/or cortical tubers
detected by MRI), and dermal manifestations. Our criteria
for intellectual disability included any degree of mental
retardation and learning disorder. The incidence of intel-
lectual disability appeared lower in patients with TSC1
mutations (3/8 = 38%) compared to that of patients with
TSC2 mutations (27/43 = 63%). However, this difference
Table 3: Polymorphisms identified for TSC1 and TSC2 in Taiwanese TSC population.
TSC1
Exon Nucleotide change Codon change Polymorphism type Frequency Reported Reference
Intron 3 c.106+15 Intron 13 (16 %) N This study
10 c.965 T>C p.M322T Missense 9 (11%) R [24]
Intron 11 c.1142-33 A>G Intron 9 (11%) R LOVDa
Intron 12 c.1264-12 T>C Intron 3 (4 %) N This study
Intron 14 c.1437-37 C>T Intron 9 (11%) R LOVDa
15 c.1726 T>C p.L576L Silent 11 (13 %) N This study
15 c.1960 C>G p.Q654E Missense 3 (4 %) N This study
Intron 18 c.2392-35 T>C Intron 9 (11%) R [24]
22 c.2829 C>T p.A943A Silent 3 (4 %) R [24]
TSC2
Exon Nucleotide change Codon change Polymorphism type Frequency Reported Reference
14 c.1593 C>T p.I531I Silent 3 (4 %) R [26]
Intron 15 c.1717-30 G>A Intron 2 (2 %) N This study
Intron 15 c.1717-27 G>A Intron 1 (1 %) N This study
Intron 21 c.2545+45 T>A Intron 11 (13 %) N This study
23 c.2652 C>T p.Y884Y Silent 1 (1 %) N This study
26 c.3126 G>T p.P1042P Silent 1 (1 %) R DKb
Intron 27 c.3285-19 C>T Intron 1 (1 %) N This study
29 c.3475 C>T p.R1159R Silent 1 (1 %) N This study
33 c.4047 G>A p.A1349A Silent 2 (2 %) N This study
Intron 33 c.4493+18 G>A Intron 1 (1 %) N This study
Intron 38 c.5069-21 G>A Intron 1 (1 %) N This study
Intron 39 c.5161-9 C>T Intron 7 (8 %) N This study
* Frequence means the number of cases in 84 Taiwanese TSC patients.
a The the Leiden Open (source) Variation Database which was available at http://chromium.liacs.nl/lovd/.
b The database of Dr David Kwiatkowski which was available at http://tsc-project.partners.org/.BMC Medical Genetics 2006, 7:72 http://www.biomedcentral.com/1471-2350/7/72
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was not statistically significant (P = 0.25), but this would
be expected because of such small sample sizes. Similarly,
the incidence of mental retardation in patients with TSC1
mutations (1/8 = 13%) appeared to be less than that of
patients with TSC2 mutations (17/43 = 40%), but this dif-
ference was not statistically significant (P = 0.23). Simi-
larly, the frequencies of renal findings, cortical tubers,
subependymal giant cell astrocytomas, liver tumors, car-
diac tumors, or skin manifestations, including
hypomelanotic macules, facial angiofibromas, shagreen
patches, and ungual fibromas did not significantly differ
between the patients with TSC1  and  TSC2  mutations.
However, all of these comparisons are under-powered due
to the relatively small number of patients with TSC1
mutations that were studied. For nearly all of the clinical
features studied, the frequencies were less for those bear-
ing TSC1 mutations than for those bearing TSC2 muta-
tions. This is consistent with findings from other large
studies, showing that TSC1  disease is less severe than
TSC2 disease [9,10,16].
Conclusion
This study is the first analysis of TSC1 and TSC2 genes in
the Taiwanese population. We identified 64 mutations
among a total of 84 patients (76%); 9 were TSC1 muta-
tions (14%) and 55 were TSC2 mutations (86%). These
numbers are similar to other studies with larger cohorts
[9,10,16-18] and would be expected if the germ line
mutation rate at the TSC2 locus were higher than that at
the TSC1  locus. The failure to detect mutations in the
Diagram depicting the locations of mutations in the TSC1 gene Figure 1
Diagram depicting the locations of mutations in the TSC1 gene. Nonsense (red), missense (blue), frameshift/in-frame (green) and 
splicing site (purple) mutations were identified.BMC Medical Genetics 2006, 7:72 http://www.biomedcentral.com/1471-2350/7/72
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remaining 24% of the patients may be due to a combina-
tion of lack of screening for large genomic deletion and
rearrangement mutations in either TSC1  or  TSC2. The
occurrence of mosaic mutations [19,20] in some of these
patients that may be difficult to detect. Another reason is
mutation detection failure.
According to previous reports, somatic and general mosa-
icism are seen in 6%-10% of all TSC patients [20,21]. In
addition, large deletions have been identified in about
2%-4% of TSC2 mutations [6] and less commonly in the
TSC1 gene [22,23]. Thus, both of these situations likely
contributed to patients in which mutations were not iden-
tified.
In summary, sixty-four different mutations were identi-
fied and characterized for the Taiwanese population. Of
those, 31 were not previously described. The diverse
mutation spectrum of TSC was also seen in different fam-
ilies and different populations.
Abbreviations
DHPLC: Denaturing high performance liquid chromatog-
raphy
Diagram depicting the locations of mutations in the TSC2 gene Figure 2
Diagram depicting the locations of mutations in the TSC2 gene. Nonsense (red), missense (blue), frameshift/in-frame (green) and 
splicing site (purple) mutations were identified.B
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Table 4: Distribution of TSC1 and TSC2 mutations.
NM M N M F M S M T o t a l
TSC1 mutaions
Familial 20 1 1 0 2  ( 3  % )
Sporadic 70 4 3 0 7  ( 1 1  % )
Total 9 0 (0 %) 5 (8 %) 4 (6 %) 0 (0 %) 9 (14 %)
TSC2 mutations
Familial 84 0 4 0 8  ( 1 3  % )
Sporadic 47 8 15 17 7 47 (73 %)
Total 55 12 (19 %) 15 (23 %) 21 (33 %) 7 (11 %) 55 (86 %)
N: screening numbers.
MM: missense mutations.
NM: nonsense mutations.
FM: frameshift/in-frame mutations.
SM: splicing site mutations.
Table 5: Clinical data of patients with TSC1 mutations
Family no. Familial/
Sporadic
Mutation 
type
Sex Onset age 
of seizure
Intellectual 
performance
Brain 
tubers
Renal 
tumors
Hepatic 
tumors
Cardiac 
rhabdomyoma
Hypomela
notic 
macules
Facial 
angiofibro
ma
Shagreen 
patch
Ungual 
fibroma
2 F FS F 2 y N + 0 NA NA 0 + 0 +
3 S NM M 8 y 3 m N + 0 0 0 + + + 0
4 1S N M F 1  y N +00 + +00 0
31 S NM F 6 m LD + + 0 + + 0 0 0
36 S FS M 2 y N + 0 0 0 + + 0 0
61 F NM M 3 y 6 m LD + 0 0 0 + + 0 0
62 S FS M 1 m LD + + 0 0 + + + +
7 2S F S M 3  y N +00 + +0+ 0
N: normal or no seizure, LD: learning disorder, MR: metal retardation, NA: not available.B
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) Table 6: Clinical data of patients with TSC2 mutations
Family no. Familial/
Sporadic
Mutation 
type
Sex Onset age 
of seizure
Intellectual 
performance
Brain 
tubers
Renal 
tumors
Hepatic 
tumors
Cardiac 
rhabdomyoma
Hypomelano
tic macules
Facial 
angiofibroma
Shagreen 
patch
Ungual 
fibroma
4S M M M 1 0  mN + + 0 0 + + + 0
5S M M F 1  y N + N A N A0 + + 0 0
6S F S M 1  mL D+ 0 0 + + 0 0 0
7 S M MM6  m M R N A N A N A N A + + 0 0
8SS F 3  mL D+ + 0 0 + + + 0
9S F S M 5  y L D+ 0 0 0 + + + 0
10 S FS F 6 m LD + 0 0 + + + 0 0
11 F FS F 4 m LD + + 0 + 0 + + 0
12 S NM M 10 m N + + 0 NA + + + 0
13 S FS F 4 m MR + NA NA + 0 0 0 0
15 F MM F 7 m MR + 0 0 0 + 0 0 0
16 S FS M 1 y N + + 3 NA + + + +
18 S FS F 5 m LD + NA NA NA + + + 0
1 9 S N MM3  m M R + + 0 N A + 0 0 0
20 S NM M 1 y 6 m N + + 0 0 + + 0 0
21 F FS F 9 y N + + 1 0 + + + +
22 F FS M 1 y LD NA NA NA NA + + + 0
23 S NM F 7 m MR + NA NA NA + 0 0 0
25 S FS M 6 m LD + 0 NA 0 + + + 0
26 S FS F 8 m LD + + 0 0 + + + 0
27 S NM M 1 y MR + + 0 0 + + 0 0
28 S NM M 3 m LD + NA NA NA + + + 0
29 S MM F 6 m MR + 0 NA 0 + 0 + 0
30 S FS F 1 y MR + + 0 0 + + 0 0
3 2 S N MM3  m N + + + 0 + + 0 0
33 S FS F 1 m N + + + 0 + + + +
34 S MM F 7 y N + + 0 0 + 0 + 0
35 S NM M 1 y MR + + 0 + + + + 0
3 7 F M MM9  m M R + 0 0 + + + + 0
39 F FS F 3 m MR + NA NA NA + + + 0
42 F MM M 7 y N 0 + + NA + + + +
47 S FS F 2 m N + 0 0 + + 0 0 0
48 S FS F 3 m MR + + 0 0 + + + 0
50 S MM M 3 m MR + NA NA NA + + + 0
53 S FS M 3 y MR + + 0 0 + + + 0
56 F MM F 2 y N + + + 0 + + + +
57 S NM F 6 m MR + 0 0 0 + + + 0
59 S S F 1 m MR + + 0 0 + + 0 0
6 4 S N MM2  m N + 0 0 0 + 0 0 0
67 S S F 3 m MR + 0 0 + + + 0 0
73 S S F 21 y N + 0 0 0 + + 0 +
75 S NM F 1 y N + + 0 0 + + 0 0
8 2 S M MM1  m N 0 0 0 + 0 0 0 0
N: normal or no seizure, LD: learning disorder, MR: metal retardation, NA: not available.BMC Medical Genetics 2006, 7:72 http://www.biomedcentral.com/1471-2350/7/72
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TSC: Tuberous sclerosis complex
CT: Computed tomography
MRI: Magnetic-resonance imaging
PCR: Polymerase chain reaction
Tm: Melting temperature
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